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INTRODUCTION
Portal vein hypoplasia (PVH), also known as pri-
mary PVH without portal hypertension, microvascu-
lar hepatic dysplasia or hepatoportal microvascular 
dysplasia (Schermerhorn et al., 1996; Cullen et al., 
2006; Berent and Weisse, 2010), is a congenital dis-
order, in which microscopic intrahepatic portovenous 
shunts are present, causing blood to bypass the liver 
sinusoids (Schermerhorn et al., 1996; Allen et al., 
1999). Microscopic shunting may occur isolated or 
may coexist with a macroscopic portosystemic shunt 
(PSS) (Schermerhorn et al., 1996; Allen et al., 1999; 
Landon et al., 2008). 
Portosystemic shunts can be divided in intra- 
and extrahepatic PSSs. Extrahepatic PSSs (EHPSS) 
usuallyoccur in small pure bred dogs, whereas intra-
hepatic PSSs are more common in large breed dogs. 
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     BSTRACT
Portal vein hypoplasia (PVH) is a congenital disorder, in which microscopic intrahepatic 
shunts are present, causing blood to bypass the liver sinusoids. As the clinical presentation and 
the laboratory findings are similar to those in dogs with an extrahepatic portosystemic shunt 
(EHPSS), differentiation between both disorders is based on the confirmation of a macroscopic 
shunt by diagnostic imaging techniques. This review highlights the major aspects of PVH, in-
cluding the differentiation from EHPSSs, and the challenges to diagnose both disorders in dogs 
with concurrent PVH and EHPSS.
SAMENVATTING
Hypoplasie van de vena portae (PVH) is een aangeboren afwijking waarbij intrahepatische, micro-
scopische shunts aanwezig zijn, waardoor het bloed niet door de leversinusoïden vloeit. De klinische 
presentatie en laboratoriumbevindingen vertonen sterke gelijkenissen met deze van patiënten met een 
extrahepatische portosystemische shunt (EHPSS). De differentiatie dient te gebeuren op basis van 
het al dan niet aanwezig zijn van een macroscopische shunt bevestigd met medische beeldvorming-
stechnieken. In dit overzichtsartikel worden de belangrijke aspecten van PVH overlopen, inclusief de 
verschillen met EHPSSs. Verder wordt ingegaan op de uitdaging om beide aandoeningen te diagnos-
ticeren bij honden die zowel PVH als een EHPSS hebben.
A
Congenital PSSs typically consist of one shunting 
vessel, in contrast to acquired PSSs that typically 
consist of multiple shunting vessels (Broome et al., 
2004; Berent and Weisse, 2007).
Dogs with PVH, PSS or the combination of both 
disorders have a similar clinicopathological presenta-
tion (Phillips et al., 1996; Allen et al., 1999; Devriendt 
et al., 2014), although the clinical presentation in dogs 
with solely PVH is generally milder or even subclini-
cal (Schermerhorn et al., 1996; Center, 2009), which 
makes it challenging to differentiate both diseases, 
especially if both are present in the same dog (Phil-
lips et al., 1996; Allen et al., 1999; Devriendt et al., 
2014). Therefore, it is likely that PVH is underdiag-
nosed. The prevalence of PVH in dogs is suggested 
to be twice to 30 times higher than the prevalence 
of PSSs (Schermerhorn et al., 1996; Center, 2009). It 
is stated that approximately 58% of dogs with PVH 
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have a concurrent congenital PSS (Richter, 2003). 
Others suggest that approximately 10% of dogs with 
a congenital PSS have additional PVH (van Straten 
et al., 2005). Although the type of PSS associated 
with PVH is often not clearly mentioned in the lit-
erature, it can be assumed that it is mostly an EHPSS, 
as PVH is typically seen in breeds that are predis-
posed for EHPSSs. In the hospital of the department 
of Medicine and Clinical Biology of Small Animals 
of the Faculty of Veterinary Medicine (UGhent), dogs 
with the combination of an EHPSS and PVH are only 
exceptionally diagnosed. Nevertheless, the diagnosis 
may be missed, especially as liver biopsies are not 
routinely taken after attenuation of the EHPSS.
SIGNALMENT AND CLINICAL PRESENTA-
TION
The same small dog breeds, such as Cairn terriers 
and Yorkshire terriers that are prone to EHPSS, are 
also predisposed to PVH (Christiansen et al., 2000). 
According to a retrospective study of Christiansen et 
al. (2000), 70% of the dogs with PVH are females. 
However, in a study of Allen et al. (1999) no sex pre-
disposition could be determined. The average age of 
dogs with PVH alone at presentation is three years 
(Allen et al., 1999; Christiansen et al., 2000), which 
is generally higher than the mean age at diagnosis for 
dogs with EHPSSs (Phillips et al., 1996; Christiansen 
et al., 2000), presumably due to less severe clinical 
signs. Although dogs with EHPSSs are usually pre-
sented before the age of two, it cannot be ruled out in 
older patients (Mertens et al., 2010).
Dogs with PSS, dogs with PVH and dogs with a 
combination of both disorders may suffer from neuro-
logical, gastrointestinal and urinary signs (Watson, 
1997; Allen et al., 1999; Christiansen et al., 2000). 
A retrospective study of Christiansen et al. (2000) 
showed that neurological signs (ranging from lethargy 
to hepatic encephalopathy) are the most common 
presenting signs. Anorexia, vomiting and diarrhea are 
the most common gastrointestinal signs, and urinary 
signs are usually associated with urolithiasis (Phil-
lips et al., 1996; Allen et al., 1999; Christiansen et al., 
2000). In dogs with PVH, the severity of the clinical 
signs is variable and related to the amount of affected 
liver lobes (Christiansen et al., 2000). The clinical 
significance of PVH is not always clear, as it often 
remains subclinical (Schermerhorn et al., 1996; Cen-
ter, 2009). Nevertheless, even if asymptomatic, the 
knowledge of the presence of PVH is clinically use-
ful when administering drugs that have a hepatic first 
pass metabolism (Center, 2009). 
DIAGNOSIS
To date, the presence of PVH cannot be dem-
onstrated in dogs that also have a patent EHPSS. 
However, it is important to consider the presence of 
PVH in any dog with an EHPSS, especially in dogs 
that have persistent clinical symptoms or laboratory 
abnormalities after surgical attenuation of a macro-
scopic shunt.
Laboratory findings
Abnormalities on blood analysis are generally 
mild and non-specific in dogs with PVH (Allen et 
al., 1999). Unlike dogs with EHPSSs, dogs with 
PVH usually do not have microcytosis (Allen et al., 
1999). Generally, serum albumin levels are normal 
to slightly decreased in dogs with PVH and liver en-
zymes might be normal to increased, depending on 
the severity of the disease. Hepatic function tests are 
suggestive of the presence of a liver disease, but none 
of them are specific. Although preprandial serum bile 
acids are often normal to mildly increased, postpran-
dial serum bile acids are usually mildly to moderately 
increased in dogs with isolated PVH (Phillips et al., 
1996) in contrast to the high pre- and postprandial 
bile acid levels encountered in most EHPSS dogs 
(Broome et al., 2004). Protein C, a vitamin K-de-
pendent anticoagulant, which is synthesized in the 
liver, may be measured in plasma. Protein C activity 
reflects the hepatic-portal perfusion (Toulza et al., 
2006; Center, 2009). Most of the dogs with PVH have 
a normal plasma protein C activity (≥ 70%), whereas 
dogs with an EHPSS tend to have a lower protein C 
activity (<70%). Sensitivity and specificity are 92.8% 
and 76%, respectively (Toulza et al., 2006). Currently, 
no commercial assay kit is available, and samples can 
only be analyzed in the United States. Recently, it has 
been suggested that rectal ammonia tolerance testing 
could possibly differentiate PVH from EHPSSs, as 
dogs with isolated PVH generally demonstrate nor-
mal ammonia clearance despite elevated pre- and 
postprandial bile acids (O’Leary et al., 2014). In this 
test, a fasting blood sample is taken and, after evacua- 
ting the rectum, an ammoniumchloride solution is 
administered rectally into the descending colon. A 
second blood sample is collected after 30 minutes and 
the blood samples should be analyzed within three 
hours (Tisdall et al., 1995). 
Diagnostic imaging 
Ultrasonography is regarded to be the best non-
invasive method for assessing the internal liver struc-
ture, including portal and hepatic vascular supply. It 
is widely available and relatively cheap (d’Anjou, 
2007), with a sensitivity for detecting PSSs using 
Doppler of 95% and a specificity up to 98% (Lamb, 
1996). However, an experienced operator is needed 
and it is a time consuming investigation (Watson, 
1997; d’Anjou et al., 2004). Unless a macroscopic 
shunting vessel can be visualized, ultrasonographic 
differentiation between dogs with EHPSSs and dogs 
with PVH is very difficult and findings are subtle 
(d’Anjou, 2007). The absence of caudal vena cava 
236 Vlaams Diergeneeskundig Tijdschrift, 2014, 83
turbulence and enlargement, a normal diameter of the 
portal vein (defined by portal vein/aorta ratio) and a 
portal mean flow velocity within normal limits com-
bined with a history suggestive of the presence of a 
PSS, may suggest the presence of PVH (d’Anjou, 
2007).
Nuclear scintigraphy is a functional imaging 
technique, in which the tracer 99mTc-pertechnetate 
is injected with ultrasound guidance into the splenic 
parenchym. The tracer is absorbed in the splenic vein, 
and in normal dogs, radioactivity in the liver is seen 
before it arrives in the heart. In dogs with a PSS to 
the contrary, radioactivity is first seen in the heart, 
before it arrives in the liver (Daniel and Berry, 2006). 
The shunt fraction provides an estimated percentage 
of portal blood bypassing the liver. In normal dogs, it 
should be less than 2.6 ± 1.3% if a transsplenic scinti-
graphy is performed (Cole et al., 2005). In dogs with 
an EHPSS, the shunt fraction is usually >84 % (Daniel 
and Berry, 2006) (Figure 1). In dogs with PVH, the 
radionuclide is distributed throughout the liver paren-
chyma, yet bypassing the hepatic sinusoids, giving 
the impression of a normal liver perfusion (Morandi 
et al., 2005; Daniel and Berry, 2006) (Figure 2). Un-
like liver function tests, scintigraphy is not influenced 
by other conditions associated with liver dysfunction 
and is thus a very sensitive test to diagnose EHPSSs 
(Landon et al., 2008).
Magnetic resonance angiography and computed 
tomography angiography are both imaging tech-
niques available to scan hepatic vascular anatomy. 
Microvascular anomalies in dogs with PVH are con-
sidered too small to be adequately visualized by these 
imaging techniques (Seguin et al., 1999; Zwingen-
berger et al., 2005), but no studies have been done in 
dogs to investigate this in detail.
Histopathology
As complete hepatic lobules are essential to evalu-
ate the internal liver structure microscopically, surgi-
cal biopsies are preferred over percutaneous needle 
or Tru Cut liver biopsies (Phillips et al., 1996). In 
dogs with EHPSSs, all liver lobes seem to be affected 
regardless of the location of the shunting vessel 
(Schermerhorn et al., 1996; Baade et al., 2006). Contra- 
rily, not all liver lobes are necessarily affected in dogs 
with PVH (Schermerhorn et al., 1996; Center, 2009). 
To diagnose PVH, biopsies of at least three differ-
ent liver lobes should be taken (Baade et al., 2006). 
The caudate lobe should preferably not be biopsied, 
since this lobe is frequently not involved in the dis-
ease (Center, 2009).
In contrast to dogs with an EHPSS, which have a 
functional hypoplasia of the portal veins, dogs with 
PVH have a morphological hypoplasia of the portal 
vessels. Portal vessels in EHPSS dogs normalize fol-
lowing successful attenuation of the shunt, whereas 
portal vessels of dogs with PVH are unresponsive 
to an increase in portal blood flow (Szatmari et al., 
2004a; Szatmari et al., 2004b). However, it is very 
difficult to differentiate between functional and mor-
phological hypoplasia histologically (Szatmari et 
al., 2004a; Landon et al., 2008). In addition to portal 
vein hypoplasia, the following histopathological fea-
Figure 1. Preoperative transsplenic scintigraphic scan 
of a five-year-old Yorkshire terrier with a shunt frac-
tion of 99%. The top left image is a composite image 
with the regions of interest (ROI): ROI 1 (red) = car-
diac area, ROI 2 (yellow) = hepatic area, ROI 3 (blue) 
= background correction. The bottom left image is a 
time-activity curve, which demonstrates the arrival of 
the activity in the heart, bypassing the liver. The image 
on the right is composed of selected frames. The path-
way of the activity is suggestive of a portoazygos shunt.
Figure 2. Transsplenic scintigraphic scan of the same 
Yorkshire terrier six months after surgical attenuation 
of the shunt. The top left image is a composite image 
with the regions of interest (ROI): ROI 1 (red) = car-
diac area, ROI 2 (yellow) = hepatic area, ROI 3 (blue) 
= background correction. The bottom left image is a 
time-activity curve, which demonstrates the arrival of 
the activity in the liver before it enters the cardiac re-
gion, indicating the absence of a portosystemic shunt. 
The image on the right is composed of selected frames. 
The calculated residual shunt fraction is 0.88%. In this 
dog, PVH was diagnosed based on histopathology (see 
Figure 4).
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tures in dogs with EHPSSs are described: arteriolar 
and ductular proliferation, mild to moderate fibrosis, 
hepatocellular atrophy and presence of lipogranulo-
mas (Baade et al., 2006; Landon et al., 2008) (Figure 
3). Dogs with PVH have similar histopathological 
features as those described in EHPSS dogs (Figure 
4). In addition, the liver of PVH dogs shows central 
venous muscular hypertrophy and an abnormal orien- 
tation of the central veins with respect to the por-
tal triads (Schermerhorn et al., 1996; Landon et al., 
2008). According to Philips et al. (1996), dogs with 
PVH have portal and periportal veins that are sig-
nificantly more dilated than in dogs with an EHPSS. 
Because of the lower degree of shunting in dogs with 
PVH relative to EHPSS dogs, their histopathologi-
cal changes are often less prominent and inconsis-
tent (Schermerhorn et al., 1996). Nevertheless, solely 
based on histopathology of the liver, it is impossible 
to differentiate between dogs affected with an EHPSS 
and/or PVH (Phillips et al., 1996; Baade et al., 2006; 
Landon et al., 2008; Center, 2009). It is worthy to 
note that liver biopsies may confirm the presence of 
PVH if an EHPSS is excluded or successfully treated. 
Immunohistochemistry (IH) is a technique in 
which antibodies are used to label proteins. In human 
medicine, it is used to differentiate liver diseases 
(Schmitt-Graff et al., 1991). Baade et al. (2006) in-
vestigated this technique in dogs with PSSs. How-
ever, the utility of IH in dogs with PVH and in dogs 
with the combination of a PSS and PVH is still un-
clear. Perisinusoidal hepatic cells are multifunctional 
mesenchymal cells, which are present between the 
sinusoids and the hepatic cells (Schmitt-Graff et al., 
1991). In normal canine livers, these cells express 
alpha-smooth muscle actin (α-SMA) and no desmin 
(Baade et al., 2006). Increased expression of α-SMA 
and desmin are signs of cellular proliferation and 
transformation of perisinusoidal hepatic cells to myo-
fibroblast-like cells (Baade et al., 2006). In inactive 
cells on the contrary, there is a decrease in the pro-
duction of α-SMA. In dogs with PSSs and in human 
patients with developing liver cirrhosis, there is an in-
creased quantity of α-SMA positive cells compared to 
normal livers (Baade et al., 2006). In human patients 
with end stage liver diseases, perisinusoidal cells are 
inactive causing a decrease of α-SMA (Schmitt-Graff 
et al., 1991). In dogs with PVH, it can be expected 
that perisinusoidal cells in the affected liver lobes are 
inactive as the microvascular shunts bypass the sinu-
soids, causing a decrease of α-SMA positive cells. In 
liver biopsies of dogs with a combination of a PSS 
and PVH, liver lobes affected with PVH may have 
a decreased amount of α-SMA, whereas other lobes 
may have an increased amount of α-SMA. These as-
sumptions remain to be studied in affected dogs.
Since all currently available tests fail to diagnose 
PVH in the presence of a patent EHPSS, further in-
vestigations should be done to define the importance 
and usefulness of IH in the future. Consistent exami-
nation of pre- and postoperative liver biopsies in dogs 
with EHPSSs may help to investigate the improve-
ment of liver morphology after shunt attenuation. 
This may also reveal if clear differences can be made 
in preoperative biopsies between dogs with solely an 
EHPSS and those with a combination of an EHPSS 
and PVH. 
TREATMENT
Since there is no macroscopic shunt to attenuate 
in dogs with PVH, medical management is the only 
treatment option currently available (Christiansen et 
al., 2000). Medical therapy is supportive and should 
be tailored to the individual patient (Christiansen 
et al., 2000). Its aim is to control the clinical signs 
by reducing encephalogenic toxins and by prevent-
Figure 4. Histopathology of the liver of a dog with PVH 
(see Figures 1 and 2): diffuse vacuolar degeneration of 
the hepatocytes, mild arteriolar proliferation (A), poorly 
differentiated periportal veins (V), some bile ducts (B) 
and the pronounced presence of lipogranuloma’s (L) 
(bar = 20µm, hematoxylin-eosin staining).
Figure 3. Histopathology of the liver of a dog with a 
patent PSS: mild arteriolar (A) and ductular (B) proli-
feration, poorly differentiated periportal veins (V) (bar 
= 20µm, hematoxylin-eosin staining).
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ing them from reaching the systemic circulation by 
means of drug administration or dietary modulations 
(Watson, 1997; Broome et al., 2004).
The majority of dogs respond well to dietary 
management alone. However, marked dietary modifi-
cation may not be indicated in every dog with PVH. It 
is recommended to give a readily digestible diet with 
a limited to moderate amount of proteins (Watson, 
1997; Christiansen et al., 2000; Berent and Weisse, 
2007) and highly digestible complex carbohydrates 
(Bexfield and Watson, 2009). Proteins should be 
of high quality and, unless hepatic encephalopathy 
is present, excessive reduction of dietary proteins 
should be avoided, as protein malnutrition may con-
tribute to hepatic degeneration and increase the need 
to break down body proteins (Watson, 1997). Several 
nutritional supplements such as vitamin E have been 
suggested as hepatoprotectants, but currently, no clear 
evidence exists regarding their efficacy (Webster and 
Cooper, 2009; Vandeweerd et al., 2013). Depending 
on the clinical symptoms and their severity, medical 
treatment is similar as in dogs with an EHPSS (Wat-
son, 1997), subclinical dogs might even not require 
any treatment (Center, 2009). Nevertheless, drugs 
that have a hepatic first-pass metabolism should be 
avoided or, if impossible, the doses given should be 
adjusted (Bexfield and Watson, 2009). Follow-up ex-
aminations should be tailored to the individual dog.
PROGNOSIS
Response to treatment and prognosis are variable 
and depend on the number of liver lobes affected by 
PVH (Center, 2009). Although PVH cannot be cured 
and medical therapy is only supportive, dogs with 
PVH seem to have a better long-term prognosis than 
non-surgically treated dogs with a PSS (Christiansen 
et al., 2000). The majority of dogs with PVH have a 
relatively good prognosis, and may have a normal life 
expectancy, even without any treatment (Christiansen 
et al., 2000; Center, 2009). Dogs presented with neuro- 
logical signs seem to have a poorer outcome (Chris-
tiansen et al., 2000). Once dogs with PVH develop 
symptoms, supportive treatment should be started as 
soon as possible, as delay may worsen the long-term 
prognosis (Christiansen et al., 2000).
CONCLUSION
Dogs with isolated PVH can display a variable 
degree of symptoms associated with hepatic dysfunc-
tion. Their clinical presentation and laboratory find-
ings are similar, but usually less pronounced than 
those found in dogs with an EHPSS. Consequently, 
most dogs with PVH are only diagnosed when they 
are older. Portal vein hypoplasia has to be differen-
tiated from an EHPSS by excluding a macroscopic 
anomalous vessel with medical imaging and by histo-
logical confirmation. The diagnosis of PVH in a dog 
with a  patent EHPSS remains a diagnostic challenge 
as none of the available diagnostic techniques (labo-
ratory findings, diagnostic imaging and histopatho-
logy of the liver) make it possible to diagnose both 
disorders at the same time. Further studies should fo-
cus on determining the actual impact of the disease 
and improving diagnostic methods. Generally, the 
prognosis in dogs with isolated PVH is good.
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